Table 7.
List of Molecules in the Late-Stage Pipeline for Acute Myeloid Leukemia (AML)
| Molecule | Class | Mechanism of action | Company | Phase (US) |
|---|---|---|---|---|
| Amonafide (AS1413) | Cytotoxic | Topoisomerase II inhibitor | Antisoma | III |
| Clofarabine | Cytotoxic | Purine nucleoside | Genzyme | III |
| Decitabine | Cytotoxic | DNA hypomethylating agent | Eisai/Johnson & Johnson | III |
| Midostaurin (PKC412) | Targeted | Flt-3 tyrosine kinase inhibitor | Novartis | III |
| PR1 peptide antigen vaccine | Immunotherapy | Peptide-based therapeutic vaccine | The Vaccine Company | III |
| Daunorubicin | Cytotoxic | Topoisomerase inhibitor | Gilead | III |
| Tipifarnib | Targeted | Farnesyl transferase inhibitor | Janssen | III |
| Theralux | Photodynamic | Radical formation stimulant | Kiadis | III |
| Lestaurtinib (CEP-701) | Targeted | TKI including Flt-3, TrkA, and JAK2 | Cephalon | III |
| Belinostat (PXD-101) | Cytotoxic | HDAC inhibitor | Spectrum Pharmaceuticals | III |
| ON 01910.Na | Cytotoxic | Cell cycle inhibitor | Onconova Therapeutics | II |